Mounjaro’s active ingredient, tirzepatide, produces more weight loss than Ozempic’s active ingredient, semaglutide, in clinical trials. People on the highest doses of tirzepatide lost roughly 20-25% of their body weight, compared to about 15% on semaglutide. But the full picture involves more than pounds on a scale. Side effects, cost, how each drug works in your body, and which version is actually approved for weight loss all factor into the decision.
A Key Distinction: Brand Names Matter
Neither Ozempic nor Mounjaro is FDA-approved for weight loss. Both are approved for type 2 diabetes. The same active ingredients are sold under different brand names specifically for weight management: semaglutide is sold as Wegovy, and tirzepatide is sold as Zepbound. The drugs are chemically identical to their diabetes counterparts, but the weight loss versions are approved at different doses and for a different patient population. If your doctor prescribes Ozempic or Mounjaro off-label for weight loss, you’re getting the same molecule, just through a different regulatory pathway.
How They Work Differently
Semaglutide (Ozempic/Wegovy) mimics a single gut hormone called GLP-1. This hormone slows stomach emptying, reduces appetite, and helps regulate blood sugar after meals. It’s a proven, well-studied mechanism that drives meaningful weight loss for most people who take it.
Tirzepatide (Mounjaro/Zepbound) mimics two gut hormones: GLP-1 and GIP. Interestingly, tirzepatide isn’t equally active at both targets. Research published in JCI Insight found that tirzepatide acts as a full, potent activator of GIP receptors while behaving as only a partial activator at GLP-1 receptors, with about 51% of the effect of the natural GLP-1 hormone. It also interacts with the GLP-1 receptor in an unusual way, triggering the appetite and blood sugar signals without causing the receptor to shut down as quickly. The practical result of this dual-hormone approach appears to be greater weight loss and, potentially, benefits across a wider range of metabolic profiles, since some people respond better to one gut hormone than the other.
Weight Loss Results
In the SURMOUNT trials, participants taking tirzepatide at the highest dose (15 mg) lost an average of 20-25% of their starting body weight over about 72 weeks. At the middle dose (10 mg), results were still substantial, typically in the 19-21% range. In the STEP trials for semaglutide at 2.4 mg (the Wegovy dose), average weight loss was around 15-17% of body weight over a similar timeframe.
That gap of roughly 5-8 percentage points is clinically significant. For someone who weighs 250 pounds, the difference could mean losing 50 pounds on semaglutide versus 60 or more on tirzepatide. Individual results vary widely, though. Some people respond exceptionally well to semaglutide and less so to tirzepatide, and vice versa. The averages tell you about populations, not about what will happen to you specifically.
Side Effects and Tolerability
Both drugs cause gastrointestinal side effects, and this is where tirzepatide’s advantage in weight loss comes with a tradeoff. A systematic review and meta-analysis in the Annals of Saudi Medicine found that overall GI side effects were significantly more common with tirzepatide than semaglutide when each was compared to placebo. Tirzepatide carried roughly a threefold increase in GI events compared to placebo (relative risk of 2.94), while semaglutide carried about a 1.7-fold increase (relative risk of 1.68).
The raw numbers are striking: about 80% of tirzepatide users in the analyzed studies reported at least one GI event, compared to roughly 31% of semaglutide users. The most common symptoms for both drugs are nausea, constipation, diarrhea, vomiting, and abdominal pain. Most of these side effects are worst during the dose escalation period and tend to improve as your body adjusts. But if you’re someone prone to stomach issues or you’ve struggled with nausea on other medications, the higher GI burden with tirzepatide is worth discussing with your prescriber.
It’s also worth noting that “any GI event” in these studies includes mild, transient nausea that resolves on its own. Severe side effects leading people to stop the medication are less common with both drugs, though still somewhat higher with tirzepatide.
Dosing and How You Take Them
Both medications are once-weekly injections using a pre-filled pen, which you administer yourself in the thigh, abdomen, or upper arm. The injection process is nearly identical for both.
Semaglutide for weight loss (Wegovy) starts at 0.25 mg weekly and titrates up gradually to a maintenance dose of 2.4 mg. Tirzepatide starts at 2.5 mg weekly and increases in 2.5 mg steps every four weeks, reaching a maintenance range of 5 to 15 mg. Your doctor determines your final maintenance dose based on how you respond and what you can tolerate. The slow titration with both drugs is designed to minimize nausea and other GI symptoms by giving your body time to adjust.
Cost Without Insurance
At list price, the weight loss versions of these drugs are both expensive but differ somewhat. Wegovy runs roughly $1,325 per month at the 1.5 mg dose level. Zepbound ranges from about $300 to $1,069 per month depending on the dose strength, with lower doses being considerably cheaper. Eli Lilly (Zepbound’s manufacturer) has been more aggressive with savings programs and direct-to-consumer pricing, which has made Zepbound somewhat more accessible for people paying out of pocket.
Insurance coverage varies enormously. Some plans cover one but not the other, some cover neither, and employer-sponsored plans have been increasingly adding or dropping coverage for GLP-1 medications as costs rise. Checking your specific formulary before committing to either drug can save you from sticker shock at the pharmacy.
Cardiovascular Benefits
Semaglutide has a proven edge in one important area: heart protection. The SELECT trial demonstrated that semaglutide reduced the risk of major cardiovascular events (heart attack, stroke, and cardiovascular death) by 20% in people with obesity and existing heart disease. This is a landmark finding that goes beyond weight loss and has changed how doctors think about treating obesity in people with cardiovascular risk.
Tirzepatide doesn’t have equivalent cardiovascular outcomes data yet. A large trial called SURMOUNT-MMO is currently evaluating whether tirzepatide reduces heart attacks, strokes, heart failure hospitalizations, and cardiovascular death in people with obesity. Until those results are available, semaglutide remains the only option in this drug class with confirmed heart protection benefits. If you have existing heart disease or significant cardiovascular risk factors, that distinction could tip the balance toward semaglutide regardless of the weight loss difference.
Which One Is Right for You
If maximum weight loss is your primary goal and you can tolerate more GI side effects, tirzepatide has the stronger track record in clinical trials. If you have heart disease or want a drug with a longer safety record and somewhat milder side effects, semaglutide is the more established choice. Cost and insurance coverage often end up being the deciding factor for many people, since both drugs are effective enough that access matters more than the percentage-point difference between them.
Some people start on one and switch to the other if they plateau or can’t tolerate the side effects. Neither drug works permanently without continued use. Most people regain a significant portion of lost weight after stopping, which makes long-term tolerability and affordability just as important as peak efficacy in the first year.